| Authors: |
Rowe SP; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas; steven.rowe@utsouthwestern.edu., Shuch BM; Department of Urology, University of California, Los Angeles, California., Ball MW; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Bex A; Department of Urology, Royal Free Hospital, London, United Kingdom, and The Netherlands Cancer Institute, Amsterdam, The Netherlands., Javadi MS; Bay Imaging Consultants Medical Group, Inc., Walnut Creek, California., Klitzke A; Division of Nuclear Medicine and Theranostics, Department of Diagnostic Imaging, Roswell Park Comprehensive Cancer Center, Buffalo, New York., Goffin K; Nuclear Medicine, University Hospitals Leuven, and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium., Mulders P; Department of Urology, Radboud University, Nijmegen, The Netherlands., Pandit-Taskar N; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Parihar AS; Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, and Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri., Viglianti BL; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, Michigan., Gorin MA; Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York; and., Herrmann K; Department of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany. |
